Antitumor effect of SN-38-releasing polymeric micelles, NK012, on spontaneous peritoneal metastases from orthotopic gastric cancer in mice compared with irinotecan

Cancer Research

Volumn 68, Issue 22, 2008, Pages 9318-9322

  Nakajima, Takako Eguchi ^a,b   Yanagihara, Kazuyoshi ^c   Takigahira, Misato ^c   Yasunaga, Masahiro ^a   Kato, Ken ^b   Hamaguchi, Tetsuya ^b   Yamada, Yasuhide ^b   Shimada, Yasuhiro ^b   Mihara, Keichiro ^d   Ochiya, Takahiro ^c   Matsumura, Yasuhiro ^a  

^a NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL   (Japan)

^c NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^d HIROSHIMA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; DRUG METABOLITE; IRINOTECAN; LUCIFERASE; NK 012; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER THERAPY; DRUG DISTRIBUTION; DRUG METABOLISM; FEMALE; FLUORESCENCE MICROSCOPY; GROWTH INHIBITION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; ORTHOTOPIC TRANSPLANTATION; PERITONEUM METASTASIS; PHOTON COUNTING TECHNIQUE; PRIORITY JOURNAL; STOMACH CANCER; TECHNIQUE; TISSUE DISTRIBUTION; TUMOR GROWTH; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; CELL LINE, TUMOR; FEMALE; HUMANS; MICE; MICE, INBRED BALB C; MICELLES; MICROSCOPY, FLUORESCENCE; PERITONEAL NEOPLASMS; STOMACH NEOPLASMS; TISSUE DISTRIBUTION;

EID: 56449127975     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-2822     Document Type: Article

References (29)

1. Koizumi W, Narahara H, Hara T, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol 2008;9:215-21.
2. Maehara Y, Moriguchi S, Orita H, et al. Lower survival rate for patients with carcinoma of the stomach of Borrmann type IV after gastric resection. Surg Gynecol Obstet 1992;175:13-6.
3. Yonemura Y. Mechanisms of drug resistance in gastric cancer. In: Yonemura Y, editor. Contemporary Approaches Toward Cure of Gastric Cancer. Kanazawa: Maeda Shoten Co. Ltd.; 1996. p. 87-91.
4. Yashiro M, Chung YS, Nishimura S, Inoue T, Sowa M. Fibrosis in the peritoneum induced by scirrhous gastric cancer cells may act as "soil" for peritoneal dissemination. Cancer 1996;77:1668-75.
5. Jain RK. Barriers to drug delivery in solid tumors. Sci Am 1994;271:58-65.
6. Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983;219:983-5.
7. Dvorak HF, Brown LF, Detmar M, Dvorak AM. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am JP athol 1995;146:1029-39.
8. Nagy JA, Masse EM, Herzberg KT, et al. Pathogenesis of ascites tumor growth: vascular permeability factor, vascular hyperpermeability, and ascites fluid accumulation. Cancer Res 1995;55:360-8.
9. Boocock CA, Charnock-Jones DS, Sharkey AM, et al. Expression of vascular endothelial growth factor and its receptors flt and KDR in ovarian carcinoma. JN atl Cancer Inst 1995;87:506-16.
10. Aoyagi K, Kouhuji K, Yano S, et al. VEGF significance in peritoneal recurrence from gastric cancer. Gastric Cancer 2005;8:155-63.
11. Maeda H, Matsumura Y, Kato H. Purification and identification of [hydroxyprolyl3]bradykinin in ascitic fluid from a patient with gastric cancer. JBiol Chem 1988;263:16051-4.
12. Matusmura Y, Maruo K, Kimura M, Yamamoto T, Konno T, Maeda H. Kinin-generating cascade in advanced cancer patients and in vitro study. Jpn J Cancer Res 1991;82:732-41.
13. Wu J, Akaike T, Hayashida K, et al. Identification of bradykinin receptors in clinical cancer specimens and murine tumor tissues. Int JCancer 2002;98:29-35.
14. Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 1986;46: 6387-92.
15. Koizumi F, Kitagawa M, Negishi T, et al. Novel SN-38-incorporating polymeric micelles, NK012, eradicate vascular endothelial growth factor-secreting bulky tumors. Cancer Res 2006;66:10048-56.
16. Nakajima TE, Yasunaga M, Kano Y, et al. Synergistic antitumor activity of the novel SN-38-incorporating polymeric micelles, NK012, combined with 5-fluorouracil in a mouse model of colorectal cancer, as compared with that of irinotecan plus 5-fluorouracil. Int JCan cer 2008;122:2148-53.
17. Saito Y, Yasunaga M, Kuroda J, Koga Y, Matsumura Y. Enhanced distribution of NK012, a polymeric micelleencapsulated SN-38, and sustained release of SN-38 within tumors can beat a hypovascular tumor. Cancer Sci 2008;99:1258-64.
18. Yanagihara K, Takigahira M, Tanaka H, et al. Development and biological analysis of peritoneal metastasis mouse models for human scirrhous stomach cancer. Cancer Sci 2005;96:323-32.
19. Yanagihara K, Takigahira M, Takeshita F, et al. A photon counting technique for quantitatively evaluating progression of peritoneal tumor dissemination. Cancer Res 2006;66:7532-9.
20. Yanagihara K, Tanaka H, Takigahira M, et al. Establishment of two cell lines from human gastric scirrhous carcinoma that possess the potential to metastasize spontaneously in nude mice. Cancer Sci 2004;95:575-82.
21. Arao T, Yanagihara K, Takigahira M, et al. ZD6474 inhibits tumor growth and intraperitoneal dissemination in a highly metastatic orthotopic gastric cancer model. Int JCancer 2006;118:483-9.
22. Slatter JG, Schaaf LJ, Sams JP, et al. Pharmacokinetics, metabolism, and excretion of irinotecan (CPT-11) following I.V. infusion of [(14)C]CPT-11 in cancer patients. Drug Metab Dispos 2000;28:423-33.
23. Rothenberg ML, Kuhn JG, Burris HA III, et al. Phase I and pharmacokinetic trial of weekly CPT-11. JClin Oncol 1993;11:2194-204.
24. Guichard S, Terret C, Hennebelle I, et al. CPT-11 converting carboxylesterase and topoisomerase activities in tumour and normal colon and liver tissues. Br J Cancer 1999;80:364-70.
25. Kawato Y, Aonuma M, Hirota Y, Kuga H, Sato K. Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res 1991;51:4187-91.
26. Araki E, Ishikawa M, Iigo M, Koide T, Itabashi M, Hoshi A. Relationship between development of diarrhea and the concentration of SN-38, an active metabolite of CPT-11, in the intestine and the blood plasma of athymic mice following intraperitoneal administration of CPT-11. Jpn J Cancer Res 1993;84: 697-702.
27. Atsumi R, Suzuki W, Hakusui H. Identification of the metabolites of irinotecan, a new derivative of camptothecin, in rat bile and its biliary excretion. Xenobiotica 1991;21:1159-69.
28. Kato K, Hamaguchi T, Shirao K, et al. Interimanalysis of phase I study of NK012, polymer micelle SN-38, in patients with advanced cancer. Proc Am Soc Clin Oncol GI 2008 (Abs #485).
29. Burris HA III, Infante JR, Spigel DR, et al. A phase I dose-escalation study of NK012. Proc Am Soc Clin Oncol 2008 (Abs #2358).